Journal article

Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome A Randomized Clinical Trial

Ian Miller, Ingrid E Scheffer, Boudewijn Gunning, Rocio Sanchez-Carpintero, Antonio Gil-Nagel, M Scott Perry, Russell P Saneto, Daniel Checketts, Eduardo Dunayevich, Volker Knappertz

JAMA Neurology | AMER MEDICAL ASSOC | Published : 2020


Importance: Clinical evidence supports effectiveness of cannabidiol for treatment-resistant seizures in Dravet syndrome, but this trial is the first to evaluate the 10-mg/kg/d dose. Objective: To evaluate the efficacy and safety of a pharmaceutical formulation of cannabidiol, 10 and 20 mg/kg/d, vs placebo for adjunctive treatment of convulsive seizures in patients with Dravet syndrome. Design, Setting, and Participants: This double-blind, placebo-controlled, randomized clinical trial (GWPCARE2) recruited patients from April 13, 2015, to November 10, 2017, with follow-up completed on April 9, 2018. Of 285 patients screened from 38 centers in the United States, Spain, Poland, the Netherlands, ..

View full abstract

University of Melbourne Researchers